SELLAS Life Sciences Group Inc. (SLS) is navigating the latter half of 2025 with multiple clinical programs in motion and a clear focus on acute myeloid leukemia or AML.
The company's development strategy centers on two assets, Galinpepimut-S (GPS), a cancer immunotherapy targeting the WT1 antigen, and SLS009, a CDK9 inhibitor, both of which are being evaluated in AML across different stages of disease.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.